Skip to main content
Veterinary Medicines

NEUMOSUIN

Authorised
  • Actinobacillus pleuropneumoniae, Serotype 5, Inactivated
  • Actinobacillus pleuropneumoniae, Serotype 4, Inactivated
  • Actinobacillus pleuropneumoniae, Serotype 2, Inactivated

Product identification

Medicine name:
NEUMOSUIN
Active substance:
  • Actinobacillus pleuropneumoniae, Serotype 5, Inactivated
  • Actinobacillus pleuropneumoniae, Serotype 4, Inactivated
  • Actinobacillus pleuropneumoniae, Serotype 2, Inactivated
Target species:
  • Pig
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Actinobacillus pleuropneumoniae, Serotype 5, Inactivated
    4.00
    billion organisms
    /
    2.00
    millilitre(s)
  • Actinobacillus pleuropneumoniae, Serotype 4, Inactivated
    4.00
    billion organisms
    /
    2.00
    millilitre(s)
  • Actinobacillus pleuropneumoniae, Serotype 2, Inactivated
    4.00
    billion organisms
    /
    2.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI09AB07
Authorisation status:
  • Valid
Authorised in:
  • Romania
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra, S.A.
Responsible authority:
  • Institute For Control Of Biological Products And Veterinary Medicines
Authorisation number:
  • 110110
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Romanian (PDF)
Published on: 27/12/2021
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."